New eye drop for dry eyes enters safety testing

NCT ID NCT07593404

Recruiting now Symptom relief Sponsor: Pleryon Therapeutics (Hangzhou) Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new lubricating eye drop called ABR2 in 40 adults with dry eye syndrome. The goal is to check if the drop is safe and tolerable when used for up to 28 days. Participants first receive a single drop in one eye, then use the drop at least twice daily for a month. This is an early-stage trial with no comparison group, so it focuses on side effects rather than effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ABR2 (ocular lubricating eye drop)
What this could lead to: If successful, this could lead to a new over-the-counter option for temporary dry eye relief.
What could go wrong: This is a very early, small safety study with no placebo group, so it cannot prove the drop works better than existing products. Side effects like eye redness or allergy are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRY EYE SYNDROME (DES) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRY EYE SYNDROME (DES)

Contacts and locations

Locations

Centre for Ocular Research & Education, School of Optometry & Vision Science, University of Waterloo
RECRUITING

Waterloo, Ontario, N2L 3G1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.